VEGFA and neoplasm: There are several potential variants for the poor outcome of anti-angiogenic therapies in clinical practice, such as the stage of the primary tumor, the level of vessel maturation, differential VEGF expression, differentiated anti-angiogenic drug efficacy in the presence of chemotherapy and the differential genetic identity of tumor endothelial cells, to name a few [9,16].